Drug Delivery of Cisplatin to Breast Cancer by Polybutylcyanoacrylate Nanoparticles

Abstract

Abstract Breast cancer is the most common cancer and the second cause of cancer‐related death in women worldwide. Chemotherapy of disease is impeded by subsequent relapse and metastasis. Nanoparticles as drug carriers have been shown the promising results. Cisplatin‐loaded polybutylcyanoacrylate ( PBCA ) nanoparticles ( NP s) were successfully constructed, and its efficacy and toxicity were evaluated on an orthotopic breast cancer model. Cisplatin‐loaded PBCA NP s were prepared by miniemulsion polymerization technique. NP s were characterized with photon correlation spectroscopy, inductively coupled plasma optical emission spectrometry ( ICP ‐ OES ) and spectrophotometry techniques. MTT assay was used to evaluate the cytotoxicity of nanodrug. To evaluate the efficacy of Cisplatin‐loaded PBCA NP s an orthotopic model of breast tumor was employed. The cell viability of nanodrug compared to that of the standard drug had a significant decrease by 75% at the first 24 h. In vivo studies showed that the number of mice treated with Cisplatin bound to PBCA NP s was significantly more than the standard drug receivers (8 against 5 mice). Considering the body weight loss as toxicity effects, nanodrug receivers were also shown significantly lesser body weight loss compared to drug receivers groups (20 against 26%).